| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A modular Phase I study of lenalidomide and paclitaxel in metastatic castration-resistant prostate cancer following prior taxane therapy
|
Mathew, P.
|
|
|
65 |
4 |
p. 811-815
|
artikel
|
| 2 |
A modular Phase I study of lenalidomide and paclitaxel in metastatic castration-resistant prostate cancer following prior taxane therapy
|
Mathew, P.
|
|
2010
|
65 |
4 |
p. 811-815
|
artikel
|
| 3 |
Amongst eligible patients, age and comorbidity do not predict for dose-limiting toxicity from phase I chemotherapy
|
LoConte, Noelle K.
|
|
2009
|
65 |
4 |
p. 775-780
|
artikel
|
| 4 |
A phase II study of sunitinib in patients with recurrent and/or metastatic non-nasopharyngeal head and neck cancer
|
Fountzilas, George
|
|
2009
|
65 |
4 |
p. 649-660
|
artikel
|
| 5 |
A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors
|
Jameson, Michael B.
|
|
2009
|
65 |
4 |
p. 791-801
|
artikel
|
| 6 |
Comparative pharmacokinetics of RAD001 (everolimus) in normal and tumor-bearing rodents
|
O’Reilly, Terence
|
|
2009
|
65 |
4 |
p. 625-639
|
artikel
|
| 7 |
Contribution of dihydropyrimidinase gene alterations to the development of serious toxicity in fluoropyrimidine-treated cancer patients
|
Fidlerova, Julie
|
|
2009
|
65 |
4 |
p. 661-669
|
artikel
|
| 8 |
Evaluation of the exposure equivalence of oral versus intravenous temozolomide
|
Diez, Blanca D.
|
|
2009
|
65 |
4 |
p. 727-734
|
artikel
|
| 9 |
Expression of nucleoside transporters, deoxycitidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer
|
Ferrandina, Gabriella
|
|
2009
|
65 |
4 |
p. 679-686
|
artikel
|
| 10 |
Gemcitabine and oxaliplatin in patients with unresectable biliary cancer including gall bladder cancer: a Korean Cancer Study Group phase II trial
|
Jang, Joung-Soon
|
|
2009
|
65 |
4 |
p. 641-647
|
artikel
|
| 11 |
Induction of apoptosis by [6]-gingerol associated with the modulation of p53 and involvement of mitochondrial signaling pathway in B[a]P-induced mouse skin tumorigenesis
|
Nigam, Nidhi
|
|
2009
|
65 |
4 |
p. 687-696
|
artikel
|
| 12 |
In vitro evaluation of pan-PI3-kinase inhibitor SF1126 in trastuzumab-sensitive and trastuzumab-resistant HER2-over-expressing breast cancer cells
|
Ozbay, Tuba
|
|
2009
|
65 |
4 |
p. 697-706
|
artikel
|
| 13 |
Molecular determinants of folate levels after leucovorin administration in colorectal cancer
|
Sadahiro, Sotaro
|
|
2009
|
65 |
4 |
p. 735-742
|
artikel
|
| 14 |
Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes
|
Jones, Alison
|
|
2009
|
65 |
4 |
p. 755-763
|
artikel
|
| 15 |
Phase II trial and prediction of response of single agent tipifarnib in patients with relapsed/refractory mantle cell lymphoma: a Groupe d’Etude des Lymphomes de l’Adulte trial
|
Rolland, Delphine
|
|
2009
|
65 |
4 |
p. 781-790
|
artikel
|
| 16 |
Population pharmacokinetic model of PI-88, a heparanase inhibitor
|
Hudachek, Susan F.
|
|
2009
|
65 |
4 |
p. 743-753
|
artikel
|
| 17 |
Progression and treatment of HER2-positive breast cancer
|
Davoli, April
|
|
2009
|
65 |
4 |
p. 611-623
|
artikel
|
| 18 |
RETRACTED ARTICLE: Induction of apoptosis by [6]-gingerol associated with the modulation of p53 and involvement of mitochondrial signaling pathway in B[a]P-induced mouse skin tumorigenesis
|
Nigam, Nidhi
|
|
|
65 |
4 |
p. 687-696
|
artikel
|
| 19 |
Safety, efficacy and pharmacokinetics of S-1 in a hemodialysis patient with advanced gastric cancer
|
Tomiyama, Nariaki
|
|
2009
|
65 |
4 |
p. 807-809
|
artikel
|
| 20 |
Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma
|
Haluska, Paul
|
|
2009
|
65 |
4 |
p. 765-773
|
artikel
|
| 21 |
Serum concentrations of pegylated interferon α-2b in patients with resected stage III melanoma receiving adjuvant pegylated interferon α-2b in a randomized phase III trial (EORTC 18991)
|
Eggermont, Alexander M. M.
|
|
2009
|
65 |
4 |
p. 671-677
|
artikel
|
| 22 |
SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo
|
Arbitrario, Jennifer P.
|
|
2009
|
65 |
4 |
p. 707-717
|
artikel
|
| 23 |
Successful rechallenge with erlotinib in a patient with EGFR-mutant lung adenocarcinoma who developed gefitinib-related interstitial lung disease
|
Fukui, Tomoya
|
|
2009
|
65 |
4 |
p. 803-806
|
artikel
|
| 24 |
Tumor-selective cytotoxicity of benzo[c]phenanthridine derivatives from Toddalia asiatica Lam.
|
Iwasaki, Hironori
|
|
2009
|
65 |
4 |
p. 719-726
|
artikel
|
Tijdschrift beschrijving